- Home
- LWAY vs ATYR Comparison
LWAY vs ATYR Comparison
Compare LWAY & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWAY
- ATYR
- Stock Information
- Founded
- LWAY 1986
- ATYR 2005
- Country
- LWAY United States
- ATYR United States
- Employees
- LWAY N/A
- ATYR N/A
- Industry
- LWAY Packaged Foods
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LWAY Consumer Staples
- ATYR Health Care
- Exchange
- LWAY Nasdaq
- ATYR Nasdaq
- Market Cap
- LWAY 376.4M
- ATYR 451.3M
- IPO Year
- LWAY 1987
- ATYR 2015
- Fundamental
- Price
- LWAY $26.47
- ATYR $5.83
- Analyst Decision
- LWAY Hold
- ATYR Strong Buy
- Analyst Count
- LWAY 1
- ATYR 6
- Target Price
- LWAY N/A
- ATYR $20.20
- AVG Volume (30 Days)
- LWAY 45.8K
- ATYR 5.4M
- Earning Date
- LWAY 08-12-2025
- ATYR 08-12-2025
- Dividend Yield
- LWAY N/A
- ATYR N/A
- EPS Growth
- LWAY N/A
- ATYR N/A
- EPS
- LWAY 0.67
- ATYR N/A
- Revenue
- LWAY $188,277,000.00
- ATYR N/A
- Revenue This Year
- LWAY $12.53
- ATYR $551.06
- Revenue Next Year
- LWAY $12.08
- ATYR $1,874.58
- P/E Ratio
- LWAY $38.59
- ATYR N/A
- Revenue Growth
- LWAY 12.84
- ATYR N/A
- 52 Week Low
- LWAY $10.06
- ATYR $1.67
- 52 Week High
- LWAY $27.29
- ATYR $7.10
- Technical
- Relative Strength Index (RSI)
- LWAY 65.90
- ATYR 54.71
- Support Level
- LWAY $24.40
- ATYR $5.15
- Resistance Level
- LWAY $27.00
- ATYR $7.10
- Average True Range (ATR)
- LWAY 0.80
- ATYR 0.55
- MACD
- LWAY 0.11
- ATYR -0.00
- Stochastic Oscillator
- LWAY 80.37
- ATYR 37.44
About LWAY Lifeway Foods Inc.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.